Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells (2010)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; DOREA, EGIDIO LIMA - HU ; CURI, RUI - ICB ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; HU; ICB
- DOI: 10.2217/pgs.10.93
- Subjects: EXPRESSÃO GÊNICA; COLESTEROL; LIPOPROTEÍNAS LDL
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Pharmacogenomics
- ISSN: 1462-2416
- Volume/Número/Paginação/Ano: v. 11, n. 9, p. 1235-1246, 2010
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
GENVIGIR, Fabiana Dalla Vecchia et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics, v. 11, n. 9, p. 1235-1246, 2010Tradução . . Disponível em: https://doi.org/10.2217/pgs.10.93. Acesso em: 19 abr. 2024. -
APA
Genvigir, F. D. V., Rodrigues, A. C., Cerda, A., Arazi, S. S., Willrich, M. A. V., Oliveira, R., et al. (2010). Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics, 11( 9), 1235-1246. doi:10.2217/pgs.10.93 -
NLM
Genvigir FDV, Rodrigues AC, Cerda A, Arazi SS, Willrich MAV, Oliveira R, Hirata MH, Dórea EL, Bernik MMS, Curi R, Hirata RDC. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells [Internet]. Pharmacogenomics. 2010 ; 11( 9): 1235-1246.[citado 2024 abr. 19 ] Available from: https://doi.org/10.2217/pgs.10.93 -
Vancouver
Genvigir FDV, Rodrigues AC, Cerda A, Arazi SS, Willrich MAV, Oliveira R, Hirata MH, Dórea EL, Bernik MMS, Curi R, Hirata RDC. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells [Internet]. Pharmacogenomics. 2010 ; 11( 9): 1235-1246.[citado 2024 abr. 19 ] Available from: https://doi.org/10.2217/pgs.10.93 - Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response
- Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
Informações sobre o DOI: 10.2217/pgs.10.93 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
